Skip to content

Insmed

US · INSM #794 by market cap Listed 1970
141.33 -3.13 -2.17%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 42.70 Expensive vs history 77th percentile
5-year average 30.01 · #496 of 511 in Biotechnology
P/E ratio -50.30 Cheap vs history 0th percentile
5-year average -12.67 · forward -1,549.49
P/S ratio 20.40 In line with history 53rd percentile
5-year average 29.38 · forward 11.31 · #229 of 392 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Insmed (INSM) 31.01B -50.30 42.70 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value155.58 Economic moatNone UncertaintyHigh

Trading 10.1% below Morningstar's fair value estimate.

Fair value

Insmed Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 7% discount to our quantitative fair value estimate of $155.58 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's balance sheet strengthens our quantitative valuation. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its EBITDA/interest coverage ratio of -6.6, which sits in the bottom 10% compared with peers globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be undervalued.

Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -2.0%, a core component of profitability, sits in the bottom 30% globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:34 · For reference only, not investment advice and not tailored to your situation.

Insmed discussion 0 comments

Add a comment